InGeneron extended its Series D financing by up to USD $23MM, totaling up to $43MM to be invested in tranches linked to development progress. Funds will support a pivotal study, now enrolling, of cell therapy in rotator cuff tendinopathy using its autologous point-of-care cell therapy portfolio.
The company is focused on cell therapies to treat pain and functional impairments associated with musculoskeletal conditions. As well as the study in rotator cuff repair, additional clinical programs underway include feasibility studies for facet joint syndrome and wrist osteoarthritis.
InGeneron extended its Series D financing by up to USD $23MM, totaling up to $43MM to be invested in tranches linked to development progress. Funds will support a pivotal study, now enrolling, of cell therapy in rotator cuff tendinopathy using its autologous point-of-care cell therapy portfolio.
The company is focused on cell therapies to...
InGeneron extended its Series D financing by up to USD $23MM, totaling up to $43MM to be invested in tranches linked to development progress. Funds will support a pivotal study, now enrolling, of cell therapy in rotator cuff tendinopathy using its autologous point-of-care cell therapy portfolio.
The company is focused on cell therapies to treat pain and functional impairments associated with musculoskeletal conditions. As well as the study in rotator cuff repair, additional clinical programs underway include feasibility studies for facet joint syndrome and wrist osteoarthritis.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
